Ashling Wahner

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

The marketing authorization application submitted to the EMA for T-DXd in HER2-positive unresectable or metastatic solid tumors has been validated.

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

The SEZ6-targeting ADC ABBV-706 generated durable efficacy outcomes comparable with those of first-line SOC in patients with relapsed/refractory SCLC.

Misty D. Shields, MD, PhD, discusses the importance of approving novel treatments for SCLC and developmental drugs that may challenge the current paradigm.

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Misty D. Shields, MD, PhD, discusses the inefficacy of concurrent immunotherapy and chemoradiation in lung cancer and the debate surrounding PCI in SCLC.

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Five experts gathered for the OncLive Peer Exchange to discuss SCLC data that continues to drive the evolving treatment paradigm.

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.